ATP disodium

Catalog No.S1985 Synonyms: Adenosine-Triphosphate disodium, ATP disodium salt, Adenosine 5'-triphosphate

For research use only.

ATP Disodium (Adenosine-Triphosphate disodium, ATP disodium salt, Adenosine 5'-triphosphate) is a disodium salt form of adenosine-triphosphate which is a multifunctional nucleoside triphosphate.

ATP disodium Chemical Structure

CAS No. 987-65-5

Selleck's ATP disodium has been cited by 11 Publications

Purity & Quality Control

Related Other Products

Biological Activity

Description ATP Disodium (Adenosine-Triphosphate disodium, ATP disodium salt, Adenosine 5'-triphosphate) is a disodium salt form of adenosine-triphosphate which is a multifunctional nucleoside triphosphate.
In vitro

ATP release and autocrine feedback through P2Y2 and A3 receptors provide signal amplification, controlling gradient sensing and migration of neutrophils. [1] ATP results in production of reactive oxygen species (ROS), which stimulates the phosphatidylinositol 3-kinase (PI3K) pathway and subsequent Akt and ERK1/2 activation. ATP-dependent ROS production and PI3K activation also stimulate transcription of genes required for an oxidative stress response. ATP-mediated ROS-dependent PI3K is required for activation of caspase-1 and secretion of IL-1beta and IL-18. [2] ATP potently stimulates TNF-alpha release, resulting from TNF-alpha mRNA expression in rat cultured brain microglia. ATP-induced TNF-alpha release is Ca(2+)-dependent, and a sustained Ca(2+) influx correlated with the TNF-alpha release in ATP-stimulated microglia. ATP-induced TNF-alpha release is inhibited by PD 098059, an inhibitor of extracellular signal-regulated protein kinase (ERK) kinase 1 (MEK1), which activates ERK, and also by SB 203580, an inhibitor of p38 mitogen-activated protein kinase. ATP rapidly activates both ERK and p38 even in the absence of extracellular Ca(2+). [3] ATP-induced cytotoxicity is mediated by classical alterations of apoptosis, including membrane blebbing, nuclear condensation, and DNA fragmentation. ATP but not other nucleotides lead to the potent and selective activation of NF-κB in microglial cells through a P2Z receptor-mediated pathway. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
1321N1 NX;WU5E3TnWwY4Tpc44h[XO|YYm= M{HreGFod26rc4SgZYN1cX[rdImgZZQhVi22ZYLtbY5idCCKQTDldIl1d3CnLYTh[4dm\CCqdX3hckBROll{IILlZ4VxfG:{IGmxNVRCKG23dHHueEBmgHC{ZYPz[YQhcW5iaIXtZY4hOTN{MV6xJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ4Ft[2m3bTDs[ZZmdCxiRVO1NF0xNjB|MEJOwG0v NWryNmhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NVkzODRpPkG5OFE6OjB2PD;hQi=>
1321N1 MUDGeY5kfGmxbjDhd5NigQ>? Mnn3RYdwdmm|dDDhZ5Rqfmm2eTDheEBPNXSncn3pcoFtKEiDIHXwbZRweGVvdHHn[4VlKHerbHSgeJlx\SB2IHj1cYFvKFB{WUKgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKGi3bXHuJFE{OjGQMTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBqdnS{YXPlcIx2dGG{IHPhcINqfW1ibHX2[YwtKEWFNUC9NE4xPjNzzszNMi=> M3r1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEG5NlA1Lz5zOUSxPVIxPDxxYU6=
1321N1 MlTwSpVv[3Srb36gZZN{[Xl? MnH4RYdwdmm|dDDhZ5Rqfmm2eTDifUBu\WG|dYLpcochcW6xc3n0c4wheGixc4DoZZRmKGGlY4XteYxifGmxbjDpckAyOzJzTkGgbJVu[W5iYYP0do9kgXSxbXGgZ4VtdHNic4ThZox6KGW6cILld5NqdmdiaIXtZY4hWDK\IID1dolvd2OncITvdkAzNCCHQ{WwQVAvODh3zszNMi=> MnTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF7OEW0O|YoRjFzOUi1OFc3RC:jPh?=
1321N1 MYXGeY5kfGmxbjDhd5NigQ>? MlfzRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQNnkzKHKnY3XweI9zKGW6cILld5Nm\CCrbjDoeY1idiBzM{KxUlEh[2WubIOgZ49mgHC{ZYPzbY5oKHCqb4PwbI9tcXCjc3WgR{1i[3SrdnH0bY5oKEdicILveIVqdiCjc4Pld5Nm\CCjczDpco9{cXSxbDDwbI9{eGijdHWgdJJw\HWldHnvckBjgSC|Y3nueIltdGG2aX;uJJBzd3irbXn0fUBie3OjeTygSWM2OD1yLkC4Oe69VS5? MmrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MUm4OlgoRjF7NEG5PFY5RC:jPh?=
1321N1 MmPESpVv[3Srb36gZZN{[Xl? NV\xTXh7SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBz\WOxbXLpcoFvfCCSMmmyJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiBzM{KxUlEh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gdIhwe3Cqb3zpdIF{\SCFLDDFR|UxRTBwMEi1{txONg>? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNyMkO5PEc,OTd|MEKzPVg9N2F-
1321N1 Mlm5SpVv[3Srb36gZZN{[Xl? M1i5VGFod26rc4SgZYN1cX[rdImgZZQhVi22ZYLtbY5idCCKQTDldIl1d3CnLYTh[4dm\CC5aXzkJJR6eGViMzDoeY1idiCSMmmyJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCqdX3hckAyOzJzTkGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcW62cnHj[YxtfWyjcjDjZYxkcXWvIHzleoVtNCCHQ{WwQVAvODl3ON88UU4> MmH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MUmyNFQoRjF7NEG5NlA1RC:jPh?=
1321N1 MofTSpVv[3Srb36gZZN{[Xl? NEGwZZVC\2:waYP0JIFkfGm4aYT5JIF1KE5vdHXycYlv[WxiSFGg[ZBqfG:yZT30ZYdo\WRiaIXtZY4hWDK\MjDy[YNmeHSxcjDSNVk1UCCvdYThcpQh\XiycnXzd4VlKGmwIHj1cYFvKDF|MkHONUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxuIFXDOVA:OC5zMUJOwG0v Ml;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MUmyNFQoRjF7NEG5NlA1RC:jPh?=
1321N1 MnXlSpVv[3Srb36gZZN{[Xl? M3LyOWFod26rc4SgZYN1cX[rdImgZZQhVi22ZYLtbY5idCCKQTDldIl1d3CnLYTh[4dm\CCqdX3hckBROll{IILlZ4VxfG:{IGmxPVhCKG23dHHueEBmgHC{ZYPz[YQhcW5iaIXtZY4hOTN{MV6xJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ4Ft[2m3bTDs[ZZmdCxiRVO1NF0xNjF{zszNMi=> M3OyblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEG5NlA1Lz5zOUSxPVIxPDxxYU6=
MDCK Ml7JSpVv[3Srb36gZZN{[Xl? MknkNVAhfU1? Mkn3TY5lfWO2aX;uJI9nKGmwdILhZ4VtdHWuYYKgZ4Ft[2m3bTDs[ZZmdCCrbjDNSGNMKGOnbHzzJIF{e2W|c3XkJIF{KG6ndDDw[YFsKH[jbIXlJIF1KDFyIIXNJIJ6KE[3cnGtNkBqdiClYXzjbZVuKG[{ZXWgcYVlcXWvLDDBZ5Rqfmm2eU2wMlE{Os7:TT6= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4M{SyOUc,OjNzNkO0NlU9N2F-
1321N1 M3fV[WZ2dmO2aX;uJIF{e2G7 NEjN[FQ{OCCvaX7z NFjifVhC\2:waYP0JIFkfGm4aYT5JIF1KEeIUDD0ZYdo\WRvaIXtZY4hWDK\MTDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hcHWvYX6gNVMzOU5zIHPlcIx{KGG|c3Xzd4VlKGG|IHXs[ZZifGmxbjDpckBk[WylaYXtJIxmfmWuIHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJJNx\WO2cn;wbI91d22ndILpZ{BidmGueYPpd{whTUN3ME2wMlE2|ryPLh?= NWj3[41LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVA3QDFpPkKxNFkxPjhzPD;hQi=>
NG108-15 MmC4SpVv[3Srb36gZZN{[Xl? Mkj4RYdwdmm|dDDhZ5Rqfmm2eTDheEBROll{IILlZ4VxfG:{IHnuJG5IOTB6LUG1JINmdGy|IDj1cotvd3ewIH;ybYdqdiluIFXDOVA:OC5zON88UU4> M4K2VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkW0PFk2Lz5{OUK1OFg6PTxxYU6=
1321N1 NYK2dGRmTnWwY4Tpc44h[XO|YYm= M{HYSWFod26rc4SgZYN1cX[rdImgZZQhVi22ZYLtbY5idCCKQTDldIl1d3CnLYTh[4dm\CCqdX3hckBROll{IILlZ4VxfG:{IGKxO|dCKG23dHHueEBmgHC{ZYPz[YQhcW5iaIXtZY4hOTN{MV6xJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ4Ft[2m3bTDs[ZZmdCxiRVO1NF0xNjF6M988UU4> NUHKe5hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NVkzODRpPkG5OFE6OjB2PD;hQi=>
HEK293 NYfjVmEzTnWwY4Tpc44h[XO|YYm= MofFRYdwdmm|dDDhZ5Rqfmm2eTDheEBROllzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBpfW2jbjDISWszQTNiY3XscJMtKEWFNUC9NE4z|ryPLh?= NUTJ[3U6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U2OTdpPkKwNVc2PTF5PD;hQi=>
HEK293 M{DtdGZ2dmO2aX;uJIF{e2G7 M1HGRWFod26rc4SgZYN1cX[rdImgZZQhemG2IGCyXVFTKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNicnXs[YF{\SCxZjDpcpRz[WOnbHz1cIFzKGOjbHPpeY0h[nliZnz1c5Jme2OnbnPlJIJie2WmIHHzd4F6NCCHQ{WwQVAvOs7:TT6= NHjo[3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki3N|Y5QCd-MkK4O|M3QDh:L3G+
CF/T43 NVTj[olqTnWwY4Tpc44h[XO|YYm= NU\PfHQySWexbnnzeEBi[3Srdnn0fUBifCCSMmmyJJJm[2WydH;yJIlvKGi3bXHuJGNHN1R2MzDj[YxteyxiRVO1NF0xNjMQvF2u NUXuOY5YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyOVQ5QTVpPkK5NlU1QDl3PD;hQi=>
BEA M4f0V2Z2dmO2aX;uJIF{e2G7 M4nwS2Fod26rc4SgZYN1cX[rdImgZZQhWDK\MjDy[YNmeHSxcjDpckBDTUFiY3XscJMhMHWwa37ve44hd3KrZ3nuLUwhTUN3ME2wMlLPxE1w NUT0XZl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyOVQ5QTVpPkK5NlU1QDl3PD;hQi=>
1321N1 NEnxN|NHfW6ldHnvckBie3OjeR?= NFTCcWNC\2:waYP0JIFkfGm4aYT5JIF1KE5vdHXycYlv[WxiSFGg[ZBqfG:yZT30ZYdo\WRiaIXtZY4hWDK\MjDy[YNmeHSxcjDSNVgxSSCvdYThcpQh\XiycnXzd4VlKGmwIHj1cYFvKDF|MkHONUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxuIFXDOVA:OC5{M{hOwG0v NWLCW2NGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NVkzODRpPkG5OFE6OjB2PD;hQi=>
1321N1 MlLOSpVv[3Srb36gZZN{[Xl? MWPB[49vcXO2IHHjeIl3cXS7IHH0JG4ufGW{bXnuZYwhUEFiZYDpeI9x\S22YXfn[YQhcHWvYX6gVFJ[OiC{ZXPldJRweiCUMUe3RX9TOThyQTDkc5VjdGVibYX0ZY51KGW6cILld5Nm\CCrbjDoeY1idiBzM{KxUlEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuLDDFR|UxRTBwMkO5{txONg>? NGDTcIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSxPVIxPCd-MUm0NVkzODR:L3G+
1321N1 Mkn0SpVv[3Srb36gZZN{[Xl? M3PrOGFod26rc4SgZYN1cX[rdImgZZQhVi22ZYLtbY5idCCKQTDldIl1d3CnLYTh[4dm\CCqdX3hckBROll{IILlZ4VxfG:{IGmxNVhCKG23dHHueEBmgHC{ZYPz[YQhcW5iaIXtZY4hOTN{MV6xJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ4Ft[2m3bTDs[ZZmdCxiRVO1NF0xNjJ7Od88UU4> MnG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2MUmyNFQoRjF7NEG5NlA1RC:jPh?=
HEK 293 M3q2RmZ2dmO2aX;uJIF{e2G7 MmPBR49v[2WwdILheIlwdiC{ZYH1bZJm\CCob4KgZ4Ft[2m3bTDtc4JqdGm8YYTpc44h[XRicnH0JJB2emmwZYLnbYMhOllzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUtiMkmzJINmdGy|LDDFR|UxRTBwNUpOwG0v NFrVdoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUOxO|Q2Oyd-MUWzNVc1PTN:L3G+
1321N1 NHjTXYVHfW6ldHnvckBie3OjeR?= M3fKVmFvfGGpb37pd5Rq[yCjY4Tpeol1gSCjdDDoeY1idiC{ZXPvcYJqdmGwdDDQNnk1KHKnY3XweI9zKGW6cILld5Nm\CCrbjCxN|IyVjFiY3XscJMtKEukPUCuO|A5|ryPLh?= NWqzbHVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezNFI{QThpPkG3N|AzOzl6PD;hQi=>
1321N1 MUjGeY5kfGmxbjDhd5NigQ>? MnrPRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDHSnAufGGpZ3XkJHAzYTGUIITyZY5{\mWldHXkJIlvKGi3bXHuJFE{OjGQMTDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcW62cnHj[YxtfWyjcjDjZYxkcXWvIH3vZoltcXqjdHnvckBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFXDOVA:OC56Nd88UU4> M3TZWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{WxNFk5Lz5{M{e1NVA6QDxxYU6=
1321N1 MVLGeY5kfGmxbjDhd5NigQ>? MlrDN|AhdWmwcx?= NEjEfGdC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHAzYTFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJIh2dWGwIEGzNlFPOSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCxZjDpcpRz[WOnbHz1cIFzKGOjbHPpeY0hdGW4ZXygZYZ1\XJiM{CgcYlveyC3c3nu[{BnfXKjLUKgRW0h[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDFR|UxRTBwOEZOwG0v MljuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NE[3PFEoRjJ2OES2O|gyRC:jPh?=
1321N1 NHyxSnFHfW6ldHnvckBie3OjeR?= MXHB[49vcXO2IHHjeIl3cXS7IHH0JGdHWC22YXfn[YQhcHWvYX6gVFJ[OVJidILhcpNn\WO2ZXSgbY4hcHWvYX6gNVMzOU5zIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIlvfHKjY3XscJVt[XJiQ3GyL{Bt\X[nbDDifUBnfXKjIEKvRW0heHKxYnWtZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDFR|UxRTBwOEZOwG0v NHfVVZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS0O|k1OCd-Mk[0OFc6PDB:L3G+
1321N1 M3rib2Z2dmO2aX;uJIF{e2G7 NYDocJZuSWexbnnzeEBi[3Srdnn0fUBifCCQLYTldo1qdmGuIFjBJIVxcXSxcHWteIFo\2WmIHj1cYFvKFB{WUKgdoVk\XC2b4KgR|I4QFNibYX0ZY51KGW6cILld5Nm\CCrbjDoeY1idiBzM{KxUlEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuLDDFR|UxRTIQvF2u NXWxe2pGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NVkzODRpPkG5OFE6OjB2PD;hQi=>
1321N1 MXrGeY5kfGmxbjDhd5NigQ>? MoLON|AhdWmwcx?= MWTBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHAzYDRicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJFE{OjGQMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGWUD3pcoR2[2WmIHP5eI9{d2yrYzDjZYxkcXWvIHnu[ox2gCClb33wc5Vv\CCycnXpcoN2[mG2ZXSg[o9zKDNyIH3pcpMh[mWob4LlJGFVWCC2cnXheI1mdnRiYomgSox2dy12IFHNJIZtfW:{ZYPj[Y5k\SCvZYToc4QtKEWFNUC9Ne69VS5? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NUC2O{c,OjNyN{WwOlc9N2F-
Sf9 NFnUdnlHfW6ldHnvckBie3OjeR?= MWPCbY5lcW6pIHHm[olvcXS7IITvJJdqdGRidInw[UA3YEircz30ZYdo\WRiaIXtZY4hUkGNMjDKTFIh\G:vYXnuJEg2OTNidH:gPFI4KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KGK7IF3BUnQuSVSSIHLpcoRqdmdiYYPzZZktKEumPUGuN:69VS5? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OjN{OU[xO{c,OzJ|Mkm2NVc9N2F-
Sf9 NVLTUFV3TnWwY4Tpc44h[XO|YYm= MlXGRolv\GmwZzDh[oZqdmm2eTD0c{A3YEircz30ZYdo\WRiaIXtZY4hUkGNMjDKTFIh\G:vYXnuJHY3OTeIIH31eIFvfCBqNUGzJJRwKDh{NzDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIGPmPUBk\WyuczDifUBOSU6WLVHUVEBjcW6maX7nJIF{e2G7LDDL[F0yNjQQvF2u MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OjN{OU[xO{c,OzJ|Mkm2NVc9N2F-
1321N1 MYfGeY5kfGmxbjDhd5NigQ>? NYTOdXlWSWOldX31cIF1cW:wIH;mJIlvd3OrdH;sJJBpd3OyaHH0[UBqdiBzM{KxUlEh[XO2cn;jfZRwdWFiY3XscJMh\XiycnXzd4lv\yCqdX3hckBROllzIID1dolvd2OncITvdkwhTUN3ME2xMlXPxE1w M4i0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzOUi1OFc3Lz5zMUm4OVQ4PjxxYU6=
Sf9 Mn7ySpVv[3Srb36gZZN{[Xl? M17BRmJqdmSrbnegZYZncW6rdImgeI8hemWlb33ibY5idnRiaIXtZY4h[mmxdHnufYxifGWmIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBifXSxcHjvd5Bpd3K7bHH0[YQhXEGNMTCoNUB1dyB|MEOgdoV{cWS3ZYOpJIZ2e2WmIIfpeIghXEGEMTCoOFM4KHSxIEWwOEBz\XOrZIXld{kh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJJNnQSClZXzsd{BjgSCVUGKgZZN{[XluIFvkQVIvQM7:TT6= M3\CU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUC5O|kyLz5{OEGwPVc6OTxxYU6=
1321N1 NXTFZYJPTnWwY4Tpc44h[XO|YYm= NXfSbIJLOzBibXnudy=> NVe0O5E5SWexbnnzeEBi[3Srdnn0fUBifCCJRmCgeIFo\2WmLXj1cYFvKFB{WUGxJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCqdX3hckAyOzJzTkGgZ4VtdHNiYYPz[ZN{\WRiYYOg[YxmfmG2aX;uJIlvKGOjbHPpeY0hdGW4ZXygZYZ1\XJiM{CgcYlveyCkeTDmcJVwemW|Y3XuZ4Uhe3CnY4Tyc5Bpd3SxbXX0dolkKGGwYXz5d4l{NCCHQ{WwQVMvO87:TT6= NUfCSlVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVA3QDFpPkKxNFkxPjhzPD;hQi=>
1321N1 MVXGeY5kfGmxbjDhd5NigQ>? MlLORYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDHSnAufGGpZ3XkJHAzYTFzUjD0doFve2[nY4Tl[EBqdiCqdX3hckAyOzJzTkGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGmwdILhZ4VtdHWuYYKgZ4Ft[2m3bTDtc4JqdGm8YYTpc44h[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDFR|UxRTZwN988UU4> MmnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NUGwPVgoRjJ|N{WxNFk5RC:jPh?=
1321N1 MkDRSpVv[3Srb36gZZN{[Xl? NU[2bllRSWexbnnzeEBi[3Srdnn0fUBifCCJRmCteIFo\2WmIHj1cYFvKFB{WUGxVkB1emGwc3\lZ5Rm\CCrbjDoeY1idiBzM{KxUlEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBE[TJtIHzleoVtKGK7IH\1doEhOi:DTTDwdo9j\S2kYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEWFNUC9Ok44|ryPLh?= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR2N{m0NEc,OjZ2NEe5OFA9N2F-
1321N1 NETzT|hHfW6ldHnvckBie3OjeR?= NGG2PItC\2:waYP0JIFkfGm4aYT5JIF1KE5vdHXycYlv[WxiSFGg[ZBqfG:yZT30ZYdo\WRiaIXtZY4hWDK\MjDy[YNmeHSxcjDSNlczSSCvdYThcpQh\XiycnXzd4VlKGmwIHj1cYFvKDF|MkHONUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxuIFXDOVA:OTFwN988UU4> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTRzOUKwOEc,OTl2MUmyNFQ9N2F-
1321N1 M4mxZmZ2dmO2aX;uJIF{e2G7 MkDFRYdwdmm|dDDhZ5Rqfmm2eTDifUBu\WG|dYLpcochcW6xc3n0c4wheGixc4DoZZRmKGGlY4XteYxifGmxbjDpckAyOzJzTkGgbJVu[W5iYYP0do9kgXSxbXGgZ4VtdHNic4ThZox6KGW6cILld5NqdmdiaIXtZY4hWDK\IID1dolvd2OncITvdkAyOSxiRVO1NF0yPy5|zszNMi=> M2HjWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzOUi1OFc3Lz5zMUm4OVQ4PjxxYU6=
1321N1 M{nF[GZ2dmO2aX;uJIF{e2G7 Mom3RY51[WexbnnzeIlkKGGldHn2bZR6KGG2IHj1cYFvKHKnY3;tZolv[W62IGCyXVQhemWlZYD0c5Ih\XiycnXzd4VlKGmwIEGzNlFPOSClZXzsdy=> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNyMkO5PEc,OTd|MEKzPVg9N2F-
MDCK MnHTSpVv[3Srb36gZZN{[Xl? MoTkNVAhfU1? NFrrcJJKdmS3Y4Tpc44hd2ZiaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuIHnuJG1FS0tiY3XscJMh[XRiMUCgeW0h[nliRoXyZU0zKGmwIHPhcINqfW1iZoLl[UBu\WSrdX2gbY4heHKnc3XuZ4Uhd2ZiMUCgeW0hXTd|M{SzJIlv[WO2aY\lJIFv[WyxZ4XlJI9nKFV5M{GyNkBxcG:|cHjvcIlx[XOnIFOgbY5pcWKrdH;y NWjFfVZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlM1OjVpPkKzNVY{PDJ3PD;hQi=>
THLP1 MYnGeY5kfGmxbjDhd5NigQ>? MYnB[49vcXO2IHHjeIl3cXS7IHH0JG5NWlB|IHnuJIh2dWGwIGTIUHAyNW63bHygZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEySUz3pcoR2[2WmIFnMMVFj\XSjIIPlZ5JmfGmxbjDifUBJTUtvQnz1[UBz\XCxcoTldkBk\WyuIHLhd4VlKGG|c3H5 MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh{OUW5PUc,Ojh6Mkm1PVk9N2F-
HEK293 NXjLOlhiTnWwY4Tpc44h[XO|YYm= MXSxJJVO NEDaUpVC\2:waYP0JIFkfGm4aYT5JIF1KEGOWD;GVHIzKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bkdy2neIDy[ZN{cW6pIFfhcJBp[XFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGmwdILhZ4VtdHWuYYKgZ4Ft[2m3bTDhZ4N2dXWuYYTpc44h[XRiMTD1UUBjgSCIbIXvMVQh\HmnIHLhd4VlKG[udX;y[ZNk\W6lZTDzdIVkfHKxcHjveI9u\XS{aXOgZZN{[Xl? MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2MUm0PVMoRjNyNEG5OFk{RC:jPh?=
HEK293 MnuySpVv[3Srb36gZZN{[Xl? Ml;nNUB2VQ>? NHHOcpRKdmS3Y4Tpc44hd2ZiaX70doFk\WyudXzhdkBk[WylaYXtJIFk[3WvdXzheIlwdiCrbjDISWszQTNiY3XscJMh[XRiMTD1UUBjgSCIbIXvMVQh\HmnIHLhd4VlKG[udX;y[ZNk\W6lZTDzdIVkfHKxcHjveI9u\XS{aXOgZZN{[Xl? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODRzOUS5N{c,OzB2MUm0PVM9N2F-
BL21(DE3) MXjGeY5kfGmxbjDhd5NigQ>? MV3BZ5Rqfmm2eTDv[kBD[WOrbHz1d{B{fWK2aXzpd{BPNXSncn3pcoFtKEircz30ZYdo\WRiQV7ULFYqKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEpTEV|KTDj[YxteyCjc4Pld5Nm\CCjczDh[IVvgWyjdHXkJJBzd2S3Y4SgZpkhVWmlaHHlcIl{NU2nboTlckBscW6ndHnjdy=> Mli1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzPDlxJ{7DbGVOSkx:L3G+
In vivo

ATP regulates microglial branch dynamics in the intact mice brain, and its release from the damaged tissue and surrounding astrocytes mediates a rapid microglial response towards injury. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Water 100 mg/mL
(181.44 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 551.14
Formula

C10H14N5O13P3.2Na

CAS No. 987-65-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04987879 Not yet recruiting Behavioral: Exercise NAFLD Milton S. Hershey Medical Center December 2021 Not Applicable
NCT05031780 Not yet recruiting Drug: Mitapivat|Other: Mitapivat-matching placebo Sickle Cell Disease Agios Pharmaceuticals Inc. December 2021 Phase 2|Phase 3
NCT04760860 Not yet recruiting Drug: Terazosin Hydrochloride|Other: Placebo Dementia With Lewy Bodies Qiang Zhang|University of Iowa October 2021 Phase 1|Phase 2
NCT04902833 Not yet recruiting Procedure: Blood Draw Pyruvate Kinase Deficiency|Pyruvate Kinase Deficiency Anemia|Hereditary Hemolytic Anemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasm|Clonal Myeloid Neoplasm|Myeloproliferative Neoplasm|Acute Myeloid Leukemia|Clonal Cytopenia of Undetermined Significance|Other Clonal Myeloid Neoplasm|Unexplained Coombs-negative Non-immune Hemolytic Anemia Massachusetts General Hospital|Agios Pharmaceuticals Inc. October 2021 --
NCT04770779 Not yet recruiting Drug: Placebo Matching Mitapivat|Drug: Mitapivat Transfusion-dependent Alpha-Thalassemia|Transfusion-dependent Beta-Thalassemia Agios Pharmaceuticals Inc. September 2021 Phase 3
NCT04770753 Not yet recruiting Drug: Placebo Matching Mitapivat|Drug: Mitapivat Non-Transfusion-dependent Alpha-Thalassemia|Non-Transfusion-dependent Beta-Thalassemia Agios Pharmaceuticals Inc. September 2021 Phase 3

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy ATP disodium | ATP disodium ic50 | ATP disodium price | ATP disodium cost | ATP disodium solubility dmso | ATP disodium purchase | ATP disodium manufacturer | ATP disodium research buy | ATP disodium order | ATP disodium mouse | ATP disodium chemical structure | ATP disodium mw | ATP disodium molecular weight | ATP disodium datasheet | ATP disodium supplier | ATP disodium in vitro | ATP disodium cell line | ATP disodium concentration | ATP disodium nmr